No correlation between clinical response to CTLA-4 blockade and presence of NY-ESO-1 antibody in patients with metastatic melanoma.
Goff
Stephanie L
SL
Robbins
Paul F
PF
El-Gamil
Mona
M
Rosenberg
Steven A
SA
D019138:Antibodies, Blocking / Q000008:administration & dosage; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D000917:Antibody Formation; D015703:Antigens, CD / Q000276:immunology*; D000951:Antigens, Neoplasm / Q000276:immunology*; D060908:CTLA-4 Antigen; D002986:Clinical Trials as Topic; D004797:Enzyme-Linked Immunosorbent Assay; D006801:Humans; D007136:Immunoglobulins / Q000097:blood; D000074324:Ipilimumab; D008545:Melanoma / Q000097:blood / Q000188:drug therapy* / Q000276:immunology* / Q000473:pathology; D008562:Membrane Glycoproteins / Q000008:administration & dosage; D008565:Membrane Proteins / Q000276:immunology*; D009362:Neoplasm Metastasis; D010446:Peptide Fragments / Q000008:administration & dosage; D058951:gp100 Melanoma Antigen
D019138:Antibodies, Blocking; D000911:Antibodies, Monoclonal; D015703:Antigens, CD; D000951:Antigens, Neoplasm; C104948:CTAG1B protein, human; D060908:CTLA-4 Antigen; C556706:CTLA4 protein, human; D007136:Immunoglobulins; D000074324:Ipilimumab; D008562:Membrane Glycoproteins; D008565:Membrane Proteins; C548637:PMEL protein, human; D010446:Peptide Fragments; D058951:gp100 Melanoma Antigen